CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

头颈部鳞状细胞癌 CAR-T 细胞治疗的进展与挑战

Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.

靶向 BCMA/CD47 的通用型 CAR-T 细胞在多发性骨髓瘤中展现出优异的抗肿瘤活性

BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.

本研究表明，靶向 BCMA/CD47 的 UCAR-T 细胞在体外和体内均表现出对 MM 强大的抗肿瘤活性，这为开发治疗多发性骨髓瘤的新型“现成”细胞免疫疗法提供了潜在策略。

BCMA 导向的 UCAR-T 细胞递送 CD47-SIRPα 检查点阻断剂增强多发性骨髓瘤的抗肿瘤疗效

Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.

利用多发性骨髓瘤中的 CD200-CD200R 免疫检查点轴增强 CAR-T 细胞治疗

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.

CRISPR/Cas9 在癌症治疗中的应用：临床转化、机制策略与治疗方向

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions.

利用 CAR-NK 细胞对抗多发性骨髓瘤：当前格局与未来方向

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

CAR-NK 疗法正从一种有前景的概念演变为针对 MM 的现实治疗平台。

CRISPR/Cas9 TCR 编辑的 NKp30 CAR-T 细胞对表达 B7H6 的白血病与黑色素瘤表现出更强的抗肿瘤免疫

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

在 BCMA-CART 细胞治疗背景下 TIGIT 阻断未能在多发性骨髓瘤小鼠模型中增强疗效

TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.

下一代肿瘤免疫治疗：CAR-T 细胞治疗的前景

Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy.